Display options
Cite
White JD, Lin H, Jia L, et al. Proceedings of the Strategy Meeting for the Development of an International Consortium for Chinese Medicine and Cancer. J Glob Oncol. 2016;3(6):814-822doi: 10.1200/JGO.2016.005710.
White, J. D., Lin, H., Jia, L., Wu, R. S., Lam, S., Li, J., Dou, J., Kumar, N., Lin, L., & Lao, L. (2017). Proceedings of the Strategy Meeting for the Development of an International Consortium for Chinese Medicine and Cancer. Journal of global oncology, 3(6), 814-822. https://doi.org/10.1200/JGO.2016.005710
White, Jeffrey D, et al. "Proceedings of the Strategy Meeting for the Development of an International Consortium for Chinese Medicine and Cancer." Journal of global oncology vol. 3,6 (2017): 814-822. doi: https://doi.org/10.1200/JGO.2016.005710
White JD, Lin H, Jia L, Wu RS, Lam S, Li J, Dou J, Kumar N, Lin L, Lao L. Proceedings of the Strategy Meeting for the Development of an International Consortium for Chinese Medicine and Cancer. J Glob Oncol. 2017 Dec;3(6):814-822. doi: 10.1200/JGO.2016.005710. Epub 2016 Oct 28. PMID: 29244995; PMCID: PMC5735960.
Copy Download .nbib Format: NLM
Share it on

J Glob Oncol. 2017 Dec;3(6):814-822. doi: 10.1200/JGO.2016.005710. Epub 2016 Oct 28.

Proceedings of the Strategy Meeting for the Development of an International Consortium for Chinese Medicine and Cancer.

Journal of global oncology

Jeffrey D White, Hongsheng Lin, Libin Jia, Roy S Wu, Stephen Lam, Jie Li, Jinhui Dou, Nagi Kumar, Lizhu Lin, Lixing Lao

Affiliations

  1. Jeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People's Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL.

PMID: 29244995 PMCID: PMC5735960 DOI: 10.1200/JGO.2016.005710

Abstract

On November 3, 2014, in Bethesda, MD, the Office of Cancer Complementary and Alternative Medicine of the National Cancer Institute held a meeting to examine the potential utility and feasibility of establishing an international consortium for Chinese medicine and cancer. There is significant interest in the West in using components of Chinese medicine (CM) -such as botanicals and herbal medicines, acupuncture and acupressure, and qigong-in the field of oncology, as potential anticancer agents, for symptom management, and to improve quality of life. The proposal for a consortium on CM came from the Chinese Academy of Chinese Medical Sciences, with the aims of improving scientific communications and collaborations and modernizing the studies of CM for cancer. The US National Cancer Institute's Office of Cancer Complementary and Alternative Medicine agreed to work with Chinese Academy of Chinese Medical Sciences to explore the feasibility of establishing an international consortium for Chinese medicine and cancer. At the meeting, participants from the United States, China, Canada, Australia, and Korea discussed issues in CM and cancer research, treatment, and management, including potential mechanisms of action, proof of efficacy, adverse effects, regulatory issues, and the need for improving the quality of randomized clinical trials of CM treatments and supportive care interventions. Presented in these proceedings are some of the main issues and opportunities discussed by workshop participants.

References

  1. Phytomedicine. 2013 Aug 15;20(11):999-1006 - PubMed
  2. Chin J Integr Med. 2011 Jun;17(6):478-80 - PubMed
  3. Invest New Drugs. 2014 Dec;32(6):1204-12 - PubMed
  4. Biochem Pharmacol. 2010 Oct 1;80(7):947-54 - PubMed
  5. Cancer Prev Res (Phila). 2011 Mar;4(3):311-23 - PubMed
  6. J Exp Clin Cancer Res. 2011 Oct 28;30:103 - PubMed
  7. Carcinogenesis. 2014 Dec;35(12):2778-86 - PubMed
  8. BMC Complement Altern Med. 2014 May 12;14:153 - PubMed
  9. Cell Death Dis. 2014 Apr 24;5:e1190 - PubMed
  10. Cancer Chemother Pharmacol. 2009 Dec;65(1):67-71 - PubMed
  11. Int J Oncol. 2012 Jun;40(6):1970-6 - PubMed
  12. Med Lett Drugs Ther. 2008 Feb 25;50(1280):15-6 - PubMed
  13. Sci Transl Med. 2010 Apr 7;2(26):26ra25 - PubMed
  14. Cancer Lett. 2014 Dec 28;355(2):232-41 - PubMed
  15. Oncogene. 2004 May 6;23(21):3841-50 - PubMed
  16. BMC Med Genomics. 2011 May 11;4:38 - PubMed
  17. Chin J Integr Med. 2011 Apr;17(4):243-5 - PubMed
  18. HIV Clin Trials. 2013 Nov-Dec;14 (6):261-73 - PubMed
  19. Asian Pac J Cancer Prev. 2011;12(7):1665-9 - PubMed
  20. Med Oncol. 2011 Dec;28 Suppl 1:S99-107 - PubMed
  21. Oncotarget. 2015 Apr 10;6(10):7365-78 - PubMed
  22. Future Oncol. 2013 Jun;9(6):909-13 - PubMed
  23. Front Med. 2011 Jun;5(2):127-33 - PubMed
  24. Mol Carcinog. 2015 Oct;54(10 ):1096-109 - PubMed
  25. JAMA. 1996 Aug 28;276(8):637-9 - PubMed
  26. Clin Cancer Res. 2011 Jan 1;17 (1):67-76 - PubMed
  27. Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1526-31 - PubMed
  28. Chin J Integr Med. 2014 Jul;20(7):496-502 - PubMed
  29. Contemp Clin Trials. 2012 Mar;33(2):279-85 - PubMed
  30. Int Immunopharmacol. 2008 Sep;8(9):1196-206 - PubMed
  31. Nat Biotechnol. 2008 Oct;26(10):1077-83 - PubMed
  32. Cancer Prev Res (Phila). 2009 Jul;2(7):634-40 - PubMed
  33. Mol Oncol. 2014 Mar;8(2):311-22 - PubMed
  34. J Clin Gastroenterol. 2012 Jul;46(6):509-14 - PubMed
  35. Am J Chin Med. 2013;41(5):1097-108 - PubMed
  36. Nutr Cancer. 2012;64(1):4-22 - PubMed
  37. Nutrients. 2014 Jul 18;6(7):2668-80 - PubMed
  38. Chin J Integr Med. 2012 Oct;18(10):730-6 - PubMed
  39. Chin J Integr Med. 2015 Sep;21(9):689-96 - PubMed
  40. Proc Chin Acad Med Sci Peking Union Med Coll. 1990;5(3):121-9 - PubMed

Substances

MeSH terms

Publication Types